Literature DB >> 9728654

Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211.

M A Walicka1, G Vaidyanathan, M R Zalutsky, S J Adelstein, A I Kassis.   

Abstract

Asynchronous Chinese hamster V79 lung fibroblasts were incubated at 37 degrees C for 30 min with the thymidine analog 5-[211At]astato-2'-deoxyuridine (211AtdU, exposure from DNA-incorporated activity) or with [211At]astatide (211At-, exposure from extracellular activity), and DNA-incorporated activity was determined. The 211AtdU content in cellular DNA increased as a function of extracellular concentration. Incorporation of 211At- was less than 1% of that of 211AtdU. After exposure, cells were frozen in the presence of 10% DMSO. One month later, survival was determined by the colony-forming assay, and DNA double-strand breaks (DSBs) were measured by the neutral elution method (pH 9.6). The survival curve for 211AtdU was biphasic (D37 = 2.8 decays per cell), reflecting killing of 211At-DNA-labeled cells and of unlabeled cells irradiated by 211At in neighboring labeled cells. The toxicity of 211At- decaying outside the cell (30-min exposure) was negligible. Analysis of the survival curve produced a D0 of 1.3 decays/cell for 211At-labeled cells. The yield of DSBs from the decay of DNA-incorporated 211At was compared with that from DNA-incorporated 125I. Each decay of 211At produced at least 10 times the number of DSBs as that obtained per 125I decay. The extreme radiotoxicity of DNA-incorporated 211AtdU seems to be associated with considerable damage to the mammalian cell genome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728654

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  9 in total

Review 1.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

Review 2.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 3.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

4.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

Review 5.  Therapeutic radionuclides: biophysical and radiobiologic principles.

Authors:  Amin I Kassis
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

6.  Microdosimetric analysis of 211At in thyroid models for man, rat and mouse.

Authors:  Anders Josefsson; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2012-06-09       Impact factor: 3.138

7.  Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model.

Authors:  R J Mairs; C L Wideman; W J Angerson; T L Whateley; M S Reza; J R Reeves; L M Robertson; A Neshasteh-Riz; R Rampling; J Owens; D Allan; D I Graham
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 8.  The potential and hurdles of targeted alpha therapy - clinical trials and beyond.

Authors:  Jörgen Elgqvist; Sofia Frost; Jean-Pierre Pouget; Per Albertsson
Journal:  Front Oncol       Date:  2014-01-14       Impact factor: 6.244

Review 9.  Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.

Authors:  Chirayu M Patel; Thaddeus J Wadas; Yusuke Shiozawa
Journal:  Molecules       Date:  2021-04-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.